| Literature DB >> 35340531 |
Prafullya Kumar Mudi1, Rajani Kanta Mahato1, Himanshu Verma2, Subhra Jyoti Panda3, Chandra Sekhar Purohit3, Om Silakari2, Bhaskar Biswas1.
Abstract
The manuscript deals with cost-effective synthesis, structural characterization and in silico SARS-CoV-2 screening activity of 5-membered heterocycle-substituted benzimidazole derivatives, 1-((1H-pyrrol-2-yl)methyl)-2-(1H-pyrrol-2-yl)-1H-benzo[d]imidazole (L1), 2-(furan-2-yl)-1-(furan-2-ylmethyl)-1H-benzo[d]imidazole (L2), 2-(thiophen-2-yl)-1-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole (L3). The benzimidazole compounds were synthesized through a green-synthetic approach by coupling of 5-membered heterocyclic-carboxaldehyde and o-phenylenediamine in water under an aerobic condition. The compounds were characterized by various spectroscopic methods and X-ray structural analysis. The suitable single-crystals of the methyl derivative of L3 were grown as L3' which crystallized in a monoclinic system and the thiophene groups co-existed in a nearly a perpendicular orientation. Further, in silico anti-SARS-CoV-2 proficiency of the synthetic derivatives is evaluated against main protease (Mpro) and non-structural proteins (nsp2 and nsp7) of SARS-CoV-2. Molecular docking and molecular dynamics analysis of the ligands (L1-L3) against Mpro and nsp2 and nsp7 for 50 ns reveal that L3 turns out to be the superlative antiviral candidate against Mpro, nsp2 and nsp7 of SARS-CoV-2 as evident from the binding score and stability of the ligand-docked complexes with considerable binding energy changes.Entities:
Keywords: 1,2-disubstituted benzimidazole; Crystal structure; Green synthesis; In silico anti-SARS-CoV-2 screening activity; MD simulations; Molecular docking
Year: 2022 PMID: 35340531 PMCID: PMC8934690 DOI: 10.1016/j.molstruc.2022.132869
Source DB: PubMed Journal: J Mol Struct ISSN: 0022-2860 Impact factor: 3.841
Scheme 1Schematic diagram of SARS-CoV-2.
Scheme 2Available benzimidazole drugs comprising heterocyclic benzimidazoles.
Scheme 3Preparative route for benzimidazoles, L1-L3 and L3ʹ.
Fig. 1(a) ORTEP diagram of the L3′ with 30% probability; (b) Formation of a 1D framework of L3′ based on NH, SH hydrogen bonding and C–Hπ (cyan dotted) along b axis; (c) Formation of the 3D crystalline architecture.
Crystallographic data and structure refinement parameters for L3.
| Empirical formula | C17.54H14N4S2 |
| Formula weight | 316.39 |
| Temperature (K) | 100 |
| Crystal system | Monoclinic |
| Space group | |
| a (Å) | 15.4110(9) |
| b (Å) | 6.2845(3) |
| c (Å) | 15.6534(9) |
| Volume (Å3) | 1468.10(14) |
| Z | 4 |
| ρ (gcm–3) | 1.434 |
| μ (mm–1) | 0.367 |
| F (000) | 661 |
| Rint | 0.063 |
| θ ranges (º) | 3.5–30.5 |
| Number of unique reflections | 3552 |
| Total number of reflections | 13,979 |
| Final R indices | 0.0727, 0.2049 |
| Largest peak and hole (eA˚−3) | 1.66, -1.22 |
Docking results for designed molecules and Covid-19 main protease (6LU7) complexes.
| S.no | Compound | LF Rank Score | LF dG | LF VSscore | LF LE | Interactions |
|---|---|---|---|---|---|---|
| 1. | -5.956 | -5.795 | -7.184 | -0.290 | 2-pi-pi stacking interactions with His 41, | |
| 2. | -5.922 | -5.747 | -6.871 | -0.287 | 2-pi-pi stacking interactions with His 41, | |
| 3. | -10.523 | -6.148 | -7.777 | -0.307 | 2-pi-pi stacking interactions with His 41, |
⁎⁎⁎LF-Rank score indicates correct energy-ranking of docked ligand poses.
* LF-dG score symbolizes accurate binding energy predictions.
⁎⁎ LF-VScore indicates correct rank-ordering of active and inactive compounds in virtual screening experiments.
⁎⁎⁎⁎LF-LE score signifies estimated ligand efficiency.
Fig. 23D docked poses for L3 in the active site of (A). main-protease; 6LU7, (B). nsp2; 7EXM and (C) nsp7; 7JLT.
Electrostatic complementarity analysis results for L3 with each of the selected targets.
| Compounds | EC | EC r | EC rho |
|---|---|---|---|
| L3-6LU7 (Covid-19-main-protease) | 0.21 | 0.377 | 0.254 |
| L3- 7EXM (nsp2) | 0.17 | -0.045 | -0.106 |
| L3- 7JLT (nsp 7) | 0.068 | -0.229 | -0.204 |
Fig. 3Electrostatic complementarity (3A and 3C) and potential analysis (3B and 3D) considering the complex of L3 and main protease.
Fig. 4RMSD plots considering the docked complexes for MD simulations at a period of 50 ns (A) L3-main protease (B) L3-nsp2 (C) L3-nsp7.
Interactions after carrying Molecular dynamics for the L3 and main protease 6LU7 complex.
| Bond type | Ligand atom | Protein atom | %Frames present |
|---|---|---|---|
| Sulfur-Ion Pair | Compound-3 Atom-S2 | A HIS 41 ND1 | 21.4% |
| Aromatic-Aromatic | Compound-3 Atom-H12 | A HIS 41 CE1 | 20.1% |
| Aromatic-Aromatic | Compound-3 Atom-H8 | A HIS 41 CE1 | 11.2% |
| Sulfur-Ion Pair | Compound-3 Atom-S1 | A ASP 187 O | 9.5% |
| Aromatic-Aromatic | Compound-3 Atom-C12 | A HIS 41 HD2 | 8.8% |
| Sulfur-Ion Pair | Compound-3 Atom-S1 | A ARG 188 O | 8.2% |
| Aromatic-Aromatic | Compound-3 Atom-H7 | A HIS 41 CE1 | 8.1% |
| Aromatic-Aromatic | Compound-3 Atom-C12 | A HIS 41 CE1 | 6.3% |
| Aromatic-Aromatic | Compound-3 Atom-H9 | A HIS 41 CE1 | 4.4% |
| Sulfur-lone Pair | Compound-3 Atom-S1 | A MET 49 O | 4.2% |
| Sulfur-Ion Pair | Compound-3 Atom-S1 | A HIS 164 O | 3.6% |
Fig. 53D interaction diagram after MD considering docked complexes (A) L3-main protease (B) nsp2 and (C) nsp7.